Literature DB >> 6983862

Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.

L W Ayers, R N Jones, A L Barry, C Thornsberry, P C Fuchs, T L Gavan, E H Gerlach, H M Sommers.   

Abstract

Cefotetan is a new, potent, 7 alpha-methoxy cephalosporin (cephamycin). The in vitro activity of cefotetan tested in a multiphasic, collaborative study against 12,260 consecutive clinical isolates and 448 selected isolates showed 93% of Enterobacteriaceae, 90% of methicillin-susceptible Staphylococcus aureus (broth dilution), 83% of Bacteroides fragilis, and 72% of non-enterococcal streptococci to be inhibited by less than or equal to 8 micrograms/ml. Beta-Lactamase-producing and -nonproducing Haemophilus influenzae strains were inhibited by less than or equal to 1.0 micrograms/ml. Cefotetan's inhibitory spectrum paralleled those of the newest generation of cephems and exceeded those of cefoxitin and cefamandole. No useful activity was present against Streptococcus faecalis or Pseudomonas aeruginosa. Cefotetan was bactericidal without significant inoculum effect and was highly resistant to hydrolysis by Richmond-Sykes types I, III, and IV beta-lactamases. Hydrolysis of the chromogenic cephalosporin PADAC (pyridine-2-azo-p-dimethylaniline cephalosporin) by type I beta-lactamases was markedly inhibited by concentrations of cefotetan similar to those of the potent inhibitor dicloxacillin. Analysis of agar disk diffusion for several disk potencies and broth dilution susceptibility tests by regression and error rate-bounding methods produced preliminary tentative zone standards (30-micrograms disk, using minimal inhibitory concentration breakpoints of less than or equal to 8 micrograms/ml susceptible and greater than 32 micrograms/ml resistant, or 75-micrograms disk, using minimal inhibitory concentration breakpoints of less than or equal to 16 micrograms/ml susceptible and greater than or equal to 64 micrograms/ml resistant) of greater than or equal to 18 mm susceptible, less than or equal to 14 mm resistant, and 15 to 17 mm indeterminate. Staphylococcus aureus testing with the 30-micrograms disk is not recommended.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6983862      PMCID: PMC185673          DOI: 10.1128/AAC.22.5.859

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  In vitro antimicrobial activity of piperacillin and seven other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase producing strains.

Authors:  C Thornsberry; C N Baker; R N Jones
Journal:  J Antimicrob Chemother       Date:  1979-03       Impact factor: 5.790

3.  Cefuroxime, an in vitro Comparison with Six Other Cephalosporins.

Authors:  A L Barry; C Thornsberry; R N Jones; P C Fuchs; T L Gavan; E H Gerlach
Journal:  Proc R Soc Med       Date:  1977

4.  Partial characterization of a beta-lactamase from Vibrio parahaemolyticus by a new automated microiodometric technique.

Authors:  R M DeBell; T M Hickey; D E Uddin
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

5.  Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; T L Gavan; E H Gerlach; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

Review 6.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

7.  In vitro evaluation of pyridine-2-azo-p-dimethylaniline cephalosporin, a new diagnostic chromogenic reagent, and comparison with nitrocefin, cephacetrile, and other beta-lactam compounds.

Authors:  R N Jones; H W Wilson; W J Novick
Journal:  J Clin Microbiol       Date:  1982-04       Impact factor: 5.948

8.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

10.  In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.

Authors:  R N Jones; A L Barry; C Thornsberry; H W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

View more
  13 in total

1.  Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods.

Authors:  R N Jones; A L Barry; P C Fuchs; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

2.  Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

3.  Susceptibilities of 45 clinical isolates of Proteus penneri.

Authors:  M Fuksa; S Krajden; A Lee
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

4.  Determination of susceptibility of anaerobic bacteria to cefotetan and cefoxitin by the thioglycolate disk elution method.

Authors:  A L Barry; R R Packer
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

Review 5.  Cephalosporins in surgery. Prophylaxis and therapy.

Authors:  D W McEniry; S L Gorbach
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 7.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

8.  Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Mechanism of resistance to some cephalosporins in Staphylococcus aureus.

Authors:  M Kono; M Sasatsu; K O'Hara; Y Shiomi; T Hayasaka
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

10.  Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus.

Authors:  Y Utsui; S Ohya; T Magaribuchi; M Tajima; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.